Used in pharmaceutical research as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK9, which plays a key role in transcription regulation. This compound shows promise in oncology for targeting cancer cells by disrupting the transcriptional machinery necessary for tumor growth and survival. It has been investigated for its antiproliferative effects in hematological malignancies and solid tumors. Its structure enables high binding affinity to the ATP-binding site of CDK9, making it a valuable tool compound in the development of targeted cancer therapies. Additionally, it serves as a molecular probe to study transcriptional control in cellular models.